Navigation Links
A New study Throws Light On The Growth & Functions Of Insulin Producing Beta Cells

The latest study that was lead by Joslin Diabetes Centre throws much needed light on how insulin-producing beta cells grow and function. These findings// they hope will help in new treatments for people with diabetes.

The Joslin Diabetes Centre in Boston, have conducted a study that now proves conclusively that two receptors in the insulin-producing beta cell do not affect in the developmental growth, which was much against a long-held hypothesis in diabetes research. This finding would help scientists in their efforts to isolate the growth factors that do stimulate beta cell growth and to understand the defects in insulin production and the reduced secretion that cause diabetes.

These two receptors have always been a major focus of research on beta cell development. Scientists have always been seeking ways to promote the growth of these essential insulin-producing cells in diabetes patients. The past two studies conducted by Joslin, the insulin receptor, a protein that mediates the action of insulin, and the receptor for insulin-like growth factor I (IGF-I), a hormone, both of which were suggested as being critical for mediating islet/beta cell development and growth, were individually 'knocked out' in beta cells in genetically altered mice.

Rohit N. Kulkarni, M.D., Ph.D., Investigator at Joslin Diabetes Centre and Assistant Professor of Medicine at Harvard Medical School, who led the latest study and was lead author in the two previous Joslin studies explained that the researchers were surprised to discover that the beta cells developed and grew normally without these receptors. He explained that previously when they knocked out one receptor at a time, the remaining receptor had compensated for the other since both are so similar. But Dr. Kulkarni, stated that this time round when they knocked out both at the same time they still didn’t find any defect in the developmental growth of beta cells. This he said made them conclude th
'"/>




Page: 1 2 3

Related medicine news :

1. A new study surpasses Gene Therapy Hurdle
2. A question on study of Adult Stem Cell
3. Marijuana gateway theory strengthened by study of twins
4. Old theory of adaptation confirmed by new study
5. Gene study links endometriosis, infertility
6. Mutant sperm beat out healthy brethren in study
7. New study questions consumption of milk for bone growth
8. New study questions consumption of milk for bone growth
9. Going to GP may delay cancer diagnosis, says new study
10. Drug addiction can be genetical, says study
11. Autism epidemic is a myth- says a new study
Post Your Comments:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ban on the sale of the soft drinks stating that it...t days round the corner, there is// every possibil...he consumption of soft drinks has bad affects on t...those in primary sections. So we are planning to b...
...nducted an international campaign to reduce the nu...ults have proved to be very fruitful and they have...ion drive was responsible for half a billion child...lobe. The death toll, which stood at 871 000 a ye...
...ture in the hill state of Himachal Pradesh that at...on an average//, with the gender ratio falling to ...is that despite such unchecked prevalence of fetic... far. The hill state of Himachal Pradesh register...
...e been suspected to contract meningococcemia, a po...characterized by high fever// and turn out to be f...n fever is caused by the bacteria Neisseria mening... blood vessels. Most commonly, the bacteria reside...
Other Medicine News:Health News:Female Ratio Drops Alarmingly In Himachal Due To Feticides 2Health News:Delhi Faces Threat of Brain Fever 2
(Date:9/4/2008)... Updated Survival Data for Ipilimumab...swire-FirstCall/ -- Medarex, Inc.,(Nasdaq: MEDX )...ipilimumab,an investigational anti-CTLA-4 antibod...presentations at the 33rd Congress of the European...ptember 12-16, 2008 in Stockholm.,Many of the foll...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Tw...ge Clinical Data Release in November 2008, BRIDGE...maceuticals,Inc., a specialty pharmaceutical comp... metabolic disease, today announced the appointmen...rd of directors., Peter Garrambone,s career inclu...
(Date:9/3/2008)... NANJING, China, Sept. 3 /PRNewswire-FirstCal...a leading manufacturer and supplier of,branded gen...ted,anti-cancer biotech product Endu (also known a...s of Endu Phase IV clinical study., At the reques...al study,to further validate the safety and therap...
(Date:9/3/2008)... September is National Vascular Diseas.../- Diffusion Pharmaceuticals,LLC, a c...zing new drugs,for the treatment of unmet medical ... patients in a Phase I/II clinical trial of its le...The trial, designated NCT00725881,on the clinicalt...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle 9131 1New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle 9131 2New Poll Announces Link Between Friends and Family Influence and a Healthy Lifestyle 9131 3Mini stress tests could help condition heart to survive major attack 9128 1Mini stress tests could help condition heart to survive major attack 9128 2WuXi PharmaTech 28NYSE 3A WX 29 Names Temporary Chairman of the Audit Committee 9125 1WuXi PharmaTech 28NYSE 3A WX 29 Names Temporary Chairman of the Audit Committee 9125 2Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 1787 1Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers 1787 2
...lects Continued Growth of Eisai,s,Commitment to On...wire/ -- Eisai,announced today that several abstra...peline compounds have been accepted for,presentati...SCO),annual meeting. ASCO takes place in Chicago f...wing and diverse oncology clinical,development pro...
... Phase II data from XL999 studies,scheduled for pr...AN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ ...linical trials of,the company,s investigational co...007 American Society of Clinical Oncology Annual,M...Chicago,Illinois. , , -- Data from the Phase I...
Other Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
...ries is a national reference laboratory and a worl... development. ARUP offers an extensive test menu o...cal and anatomic pathology. Owned by the Universit... than half of the nation's university teaching hos...
Medicine Products: